Selected article for: "control case and study participate"
Author: Generali, Daniele; Bosio, Giancarlo; Malberti, Fabio; Cuzzoli, Antonio; Testa, Sophie; Romanini, Laura; Fioravanti, Antonio; Morandini, Alessandro; Pianta, Luca; Giannotti, Guglielmo; Viola, Erika Maria; Pier-Franceschi, Matteo Giorgi; Foramitti, Marina; Tira, Rosa Angela; Zangrandi, Ilaria; Chiodelli, Giulia; Machiavelli, Andrea; Cappelletti, Maria Rosa; Giossi, Alessia; De Giuli, Valeria; Costanzi, Chiara; Campana, Chiara; Bernocchi, Ottavia; Sirico, Marianna; Zoncada, Alessia; Molteni, Alfredo; Venturini, Sergio; Giudici, Fabiola; Scaltriti, Maurizio; Pan, Angelo
Title: Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study
  • Cord-id: 5cb8w9fd
  • Document date: 2020_12_29
    • ID: 5cb8w9fd
    Snippet: OBJECTIVES: Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. We studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study; 33 patients (Cases) signed informed consent and received canaki
    Document: OBJECTIVES: Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. We studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study; 33 patients (Cases) signed informed consent and received canakinumab (Cohort 1); 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (SoC), (Cohort 2). RESULTS: Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs 26 days, respectively; p < 0.001). There was significant clinical improvement in ventilation regimes following administration of canakinumab compared to Cohort 2 (Stuart-Maxwell test for paired data, p < 0.001). Patients treated with canakinumab experienced a significant increase in PaO(2):FiO(2) (p < 0.001) and reduction in lung damage by CT (p = 0.01), along with significant decreases in immune/inflammation markers that were not observed in Cohort 2. Only mild side effects were seen in patients treated with canakinumab; survival at 60 days was 90.0% (95% CI: 71.9-96.7) in patients treated with canakinumab and 73.3% (95% CI: 43.6-89.1) for Cohort 2. CONCLUSIONS: Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favorable prognosis versus SoC.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and long term safety: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir antiviral drug: 1
    • acute ards respiratory distress syndrome and low dosage: 1, 2
    • acute ards respiratory distress syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission reduce and lopinavir ritonavir: 1
    • long term safety and lopinavir ritonavir: 1, 2
    • long term safety and lung involvement: 1
    • lopinavir ritonavir and low dosage: 1
    • lopinavir ritonavir and low respiratory: 1, 2
    • lopinavir ritonavir and low respiratory tract: 1
    • lopinavir ritonavir and lung damage: 1, 2, 3, 4, 5, 6
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5
    • lopinavir ritonavir and lung opacity: 1, 2
    • low dosage and lung involvement: 1
    • low respiratory and lung damage: 1, 2, 3